Table 3.

Summary of the clinicopathological characteristics of Group 3 patients.

Case No.	Sex	Age	Primary Location	Tissue Origin	Grade	Preoperative Therapy	SSTR2 Immunoreactivity			Treatment	Response to SSA	SD, CR = Positive PD = Negative
							Volante Score	IRS	DIA *
1	M	63	midgut	primary site	G1	TS1, Octreotide	2	4	769	Octreotide, UFT	CR	positive
2	F	60	hindgut	primary site	G2	Not done	2	6	1492	Lanreotide	SD	positive
3	M	55	midgut	primary site	G2	Not done	3	12	1741	Lanreotide	SD	positive
4	M	61	hindgut	primary site	G2	Octreotide	1	0	163	Octreotide	SD	positive
5	F	45	hindgut	primary site	G1	Octreotide, Lanreotide	2	2	1075	Octreotide, Lanreotide	SD	positive
6	M	65	hindgut	primary site	G2	Not done	2	4	898	Octreotide, Lanreotide	SD	positive
7	M	48	hindgut	metastatic site (liver)	G2	Octreotide, Lanreotide	2	2	830	Octreotide, Lanreotide	PD	negative
8	M	72	midgut	metastatic site (liver)	G2	Octreotide, Lanreotide	2	4	731	Octreotide, Lanreotide	PD	negative
9	M	61	foregut	primary site	G2	Not done	2	12	2379	Octreotide	PD	negative
10	M	73	foregut	metastatic site (liver)	G2	Not done	1	0	215	Lanreotide	PD	negative
11	M	74	midgut	primary site	G1	Not done	2	8	1240	Lanreotide	SD	positive
12	F	65	foregut	metastatic site (liver)	G1	Octreotide	2	8	1467	Octreotide	SD	positive
13	F	67	midgut	primary site	G1	Octreotide, Everolimus	2	2	967	Octreotide	SD	positive
14	F	71	hindgut	primary site	G2	Not done	2	4	1027	5FU, CDDP, Octreotide	SD	positive

* Round down after the decimal point. Abbreviations: IRS—immunoreactive score; DIA—digital image analysis; SSA—somatostatin analogue; UFT—uracil-tegafur; 5FU—5-fluorouracile; CDDP—cisplatin; SD—stable disease; CR—complete response; PD—progressive disease.